CN110770586A - Il-10、s100b和h-fabp标记及其在创伤性脑损伤检测中的应用 - Google Patents

Il-10、s100b和h-fabp标记及其在创伤性脑损伤检测中的应用 Download PDF

Info

Publication number
CN110770586A
CN110770586A CN201880039652.2A CN201880039652A CN110770586A CN 110770586 A CN110770586 A CN 110770586A CN 201880039652 A CN201880039652 A CN 201880039652A CN 110770586 A CN110770586 A CN 110770586A
Authority
CN
China
Prior art keywords
tbi
protein
fabp
group
mtbi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880039652.2A
Other languages
English (en)
Chinese (zh)
Inventor
J-C·桑切斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Geneva
Original Assignee
University of Geneva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Geneva filed Critical University of Geneva
Publication of CN110770586A publication Critical patent/CN110770586A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201880039652.2A 2017-06-15 2018-06-07 Il-10、s100b和h-fabp标记及其在创伤性脑损伤检测中的应用 Pending CN110770586A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17001015.1 2017-06-15
EP17001015 2017-06-15
PCT/EP2018/065090 WO2018228927A1 (en) 2017-06-15 2018-06-07 Il-10, s100b and h-fabp markers and their use in detecting traumatic brain injury

Publications (1)

Publication Number Publication Date
CN110770586A true CN110770586A (zh) 2020-02-07

Family

ID=59091305

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880039652.2A Pending CN110770586A (zh) 2017-06-15 2018-06-07 Il-10、s100b和h-fabp标记及其在创伤性脑损伤检测中的应用

Country Status (6)

Country Link
US (1) US20200174015A1 (cg-RX-API-DMAC10.html)
EP (1) EP3639034A1 (cg-RX-API-DMAC10.html)
JP (1) JP2020525765A (cg-RX-API-DMAC10.html)
CN (1) CN110770586A (cg-RX-API-DMAC10.html)
AU (1) AU2018283348A1 (cg-RX-API-DMAC10.html)
WO (1) WO2018228927A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115170540A (zh) * 2022-07-26 2022-10-11 浙江工业大学 一种基于多模态影像特征融合的轻度创伤性脑损伤分类方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113366318A (zh) * 2019-01-31 2021-09-07 日内瓦大学 创伤性脑损伤(tbi)的前瞻性标志物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008008819A2 (en) * 2006-07-11 2008-01-17 University Of Florida Research Foundation, Inc. Diagnosis and treatment of neurological inflammation
WO2016055148A2 (en) * 2014-10-06 2016-04-14 Université De Genève Markers and their use in brain injury
CN106461645A (zh) * 2014-04-07 2017-02-22 铁马诊断公司 外伤性脑损伤和神经退行性生物标记物、方法和系统

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120322682A1 (en) * 2011-06-20 2012-12-20 William Marsh Rice University Brain injury biomarker panel

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008008819A2 (en) * 2006-07-11 2008-01-17 University Of Florida Research Foundation, Inc. Diagnosis and treatment of neurological inflammation
CN106461645A (zh) * 2014-04-07 2017-02-22 铁马诊断公司 外伤性脑损伤和神经退行性生物标记物、方法和系统
WO2016055148A2 (en) * 2014-10-06 2016-04-14 Université De Genève Markers and their use in brain injury

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAVITA SINGH等: "Longitudinal changes in the DTI measures, anti-GFAP expression and levels of serum inflammatory cytokines following mild traumatic brain injury", 《EXPERIMENTAL NEUROLOGY》 *
PRAMOD K. DASH等: "Biomarkers for the Diagnosis, Prognosis, and Evaluation of Treatment Efficacy for Traumatic Brain Injury", 《NEUROTHERAPEUTICS》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115170540A (zh) * 2022-07-26 2022-10-11 浙江工业大学 一种基于多模态影像特征融合的轻度创伤性脑损伤分类方法

Also Published As

Publication number Publication date
WO2018228927A1 (en) 2018-12-20
US20200174015A1 (en) 2020-06-04
JP2020525765A (ja) 2020-08-27
AU2018283348A1 (en) 2020-01-02
EP3639034A1 (en) 2020-04-22

Similar Documents

Publication Publication Date Title
AU2015330355B2 (en) Markers and their use in brain injury
Wang et al. Thorough overview of ubiquitin C‐terminal hydrolase‐L1 and glial fibrillary acidic protein as tandem biomarkers recently cleared by US Food and Drug Administration for the evaluation of intracranial injuries among patients with traumatic brain injury
Mahan et al. Glial fibrillary acidic protein (GFAP) outperforms S100 calcium-binding protein B (S100B) and ubiquitin C-terminal hydrolase L1 (UCH-L1) as predictor for positive computed tomography of the head in trauma subjects
Swindell et al. ALS blood expression profiling identifies new biomarkers, patient subgroups, and evidence for neutrophilia and hypoxia
Chabok et al. Neuron-specific enolase and S100BB as outcome predictors in severe diffuse axonal injury
Whistler et al. Integration of gene expression, clinical, and epidemiologic data to characterize Chronic Fatigue Syndrome
Flicker et al. Mild cognitive impairment in the elderly: predictors of dementia
JP2023531521A (ja) 神経損傷および疾患を検出、予後判定、およびモニタリングするためのマルチモダリティシステムおよび方法
Papassotiropoulos et al. Screening for depression in the elderly: a study on misclassification by screening instruments and improvement of scale performance
Puravet et al. Can the association of the biomarkers GFAP and UCH-L1 predict intracranial injury after mild traumatic brain injury in adults? A systematic review and meta-analysis
US20220137072A1 (en) Markers and their use in brain injury
Seubert-Ravelo et al. Mild cognitive impairment in patients with early-onset Parkinson's disease
Kim et al. Procalcitonin as a diagnostic and prognostic factor for tuberculosis meningitis
US20160187354A1 (en) Diagnostic markers for multiple sclerosis
Kuchenbecker et al. Diagnostic utility of cerebrospinal fluid biomarkers in patients with rapidly progressive dementia
CN119626532A (zh) 一种肌萎缩侧索硬化症预测及预后评估系统
Lanni et al. Unfolded p53 in blood as a predictive signature signature of the transition from mild cognitive impairment to Alzheimer's disease
US20200174015A1 (en) Il-10, s100b and h-fabp markers and their use in detecting traumatic brain injury
Li et al. Microglial/macrophage activation in the cerebrospinal fluid of neuromyelitis optica spectrum disorders
Simonsen et al. Protein markers for the differential diagnosis of vascular dementia and Alzheimer’s disease
CN110396538A (zh) 偏头痛生物标志物及其用途
JP7519094B2 (ja) 自閉症スペクトラム障害の診断方法
JP2020525765A5 (cg-RX-API-DMAC10.html)
CN112063709A (zh) 一种以微生物作为诊断标志物的重症肌无力的诊断试剂盒及应用
CN117741143B (zh) Siglec-9蛋白及其特异性抗体在制备神经梅毒或神经损伤诊断产品中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200207